Tanaka K et al. suggested that oncogenic gene mutations were prevalent in youngers with lung adenocarcinoma, moreover, the positive rates of ALK fusions, HER-2 mutations, ROS1 fusions, and RET rearrangement were higher in younger lung cancer patients than in elderly patients, indicating that younger patients are more likely to benefit from targeted therapy [23]. The gene discussed is ROS1; the disease is lung carcinoma.